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Abstract: Phage display technology has been demonstrated to be a powerful tool for screening 
useful ligands that are capable of specifically binding to biomarkers on the surface of tumor 
cells. The ligands found by this technique, such as peptides, have been successfully applied 
in the fields of early cancer diagnostics and chemotherapy. In this study, a novel nonsmall cell 
lung cancer-targeting peptide (LCTP, sequence RCPLSHSLICY) was screened in vivo using 
a Ph.D.-C7CTM phage display library. In order to develop a universal tumor-targeting drug 
  carrier, the LCTP and fluorescence-labeled molecule (FITC) were conjugated to an acetylated 
polyamidoamine (PAMAM) dendrimer of generation 4 (G4) to form a PAMAM–Ac–FITC–
LCTP conjugate. The performance of the conjugate was first tested in vitro. In vitro results of 
cell experiments analyzed by flow cytometry and inverted fluorescence microscopy indicated 
that PAMAM–Ac–FITC–LCTP was enriched more in NCI-H460 cells than in 293T cells, and 
cellular uptake was both time- and dose-dependent. The tissue distribution of the conjugate in 
athymic mice with lung cancer xenografts was also investigated to test the targeting efficiency 
of PAMAM–Ac–FITC–LCTP in vivo. The results showed that LCTP can effectively facilitate 
the targeting of PAMAM–Ac–FITC–LCTP to nonsmall cell lung cancer cells and tumors. These 
results suggest that the LCTP-conjugated PAMAM dendrimer might be a promising drug carrier 
for targeted cancer diagnosis and treatment.
Keywords: polyamidoamine dendrimer, in vivo phage display, targeted drug delivery, peptide, 
nonsmall cell lung cancer
Introduction
Nonspecific anticancer chemotherapy has no tumor targeting effect and will kill normal 
and cancer cells, causing severe side effects in many patients. To solve this problem, 
targeted drug delivery systems have received great attention.1 In this system, drugs 
can be specifically targeted to the tumors, increase drug solubility,2,3 prolong time of 
drugs in the circulation, protect drugs from degradation, and improve their metabolic 
kinetics.4,5 To date, liposomes,6 micelles,7,8 and dendrimers9 conjugated with specific 
ligands have been identified as being able to target drugs to cancer cells.
Polyamidoamine (PAMAM) dendrimers have attracted considerable research inter-
est as drug carriers due to their unique properties, ie, hyperbranched and monodispersed 
tree-like structures with multifunctional surfaces, enabling the   dendrimers to encapsu-
late or conjugate drug molecules. Moreover, the terminal groups of PAMAM can be 
easily modified (by, eg, acetylation or poly(ethyleneglycol) modification [PEGylation]) 
to improve their   solubility and biocompatibility. In order to improve the targeting capa-
bility of PAMAM, many targeting molecules, such as antibodies,10 folic acid,11,12 biotin,13 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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peptides,14–17 and carbohydrates18,19 have been connected to 
PAMAM   dendrimers. Finally, chemotherapy drugs have been 
  covalently bound to these dendrimers20,21 or   encapsulated in 
the internal cavities of dendritic molecules11,22 to generate 
targeted drug delivery systems.
A key factor of a targeted drug delivery system is the 
finding of targeting molecules that can specifically   recognize 
tumor and cancer cells. Phage display technology is a   powerful 
approach to screening targeting molecules, such as peptides, 
for cancer cells or tumor blood vessel endothelial cells.23,24 
Many novel angiogenic vessels and homing peptides have 
been isolated recently using this method.17,25,26   Furthermore, 
in vivo phage display can screen cancer-binding peptides 
regardless of whether the receptor is known or not. Therefore, 
this technique can quickly screen   cancer-specific peptides.27,28 
In addition to drug delivery systems,   tumor-targeting peptides 
are also employed in diagnosis or radiotherapy by delivering 
radionuclide.29–31 Some peptides discovered by phage display 
are even able to inhibit cancer growth and induce cancer cell 
apoptosis.32,33
In order to develop a universal drug carrier for nonsmall 
cell lung cancer chemotherapy, a Ph.D.-C7CTM (New England 
Biolabs, Beverly, MA) phage display library was utilized to 
screen peptides specific for nonsmall cell lung cancer. It has 
become generally accepted that organs have their own special 
markers. Such heterogeneity was reported after it became 
apparent that endothelial cells in different organs display 
organ-specific markers. The phage display library includes 
all possible peptide sequences, and some random peptides 
displayed by phage can bind specifically with tumor-specific 
markers displayed by nonsmall cell lung cancer, based on 
protein–protein interactions. The phage displaying specific 
peptides would home to the tumor site, after intravenous 
injection. The tumor is then harvested and the phage therein 
collected and amplified. After four to five rounds, the phage 
including the tumor-specific targeting peptide can be isolated 
and the inserted peptide sequence translated by the phage 
DNA sequence. In our study, a novel peptide, lung cancer- 
targeting peptide (LCTP; RCPLSHSLICY), was discovered 
which can specifically target nonsmall cell lung cancer. The 
LCTP was then conjugated with fluorescein  isothiocyanate 
(FITC, a fluorescence labeling agent used as a tracer) and 
acetylated PAMAM to generate a targeted drug delivery 
carrier (PAMAM–Ac–FITC–LCTP). The performance of 
this drug carrier was evaluated by in vitro culturing  NCI-
H460 and 293T cells and in vivo using athymic mice with 
lung cancer xenografts. Our results showed that the   modified 
PAMAM peptide dendrimer could be easily taken up by 
  NCI-H460 cells in vitro and by tumors in vivo.
Materials and methods
Materials
Phenyl methyl sulphonyl fiuoride (PMSF), isopropyl β-D-1-
thiogalactopyranoside (IPTG), aprotinin,   leupeptin, 5-bromo-
4-chloro-3- indolyl-β-D-galactopyranoside (X-gal), FITC, 
5,5-dithiobis-2-nitrobenzoic acid (DTNB), and polyamido-
amine (G 4) were purchased from Sigma-Aldrich (St Louis, 
MO). Dialysis membrane (MWCO, 3500) was purchased 
from BBI Inc (Shanghai, China). 3-(4,5-dimethylthiazol-2-
yl)-2,5-  diphenyl tetrazolium bromide (MTT), all cell culture 
media, and supplies were purchased from Gibco Corporation 
(Grand Island, NE).
The NCI-H460 cell line was kindly provided by Dr Yong 
Wang (Institute of Radiation Medicine, Chinese Academy of 
Medical Sciences, Tianjin, China). The 293T cell line was 
purchased from Keygen Co (Nanjing, China). Phage DNA 
sequencing was performed by Shanghai Sangon Corp (Shang-
hai, China). Peptides were synthesized by GL   Biochem Ltd 
(Shanghai, China). BALB/c-nu/nu athymic mice (female, 4–6 
weeks old) were purchased from the Laboratory   Animal Cen-
ter of The Academy of Military Medical Sciences (Beijing, 
China). The animal studies were performed in accordance 
with the Regulations for the Administration of Affairs Con-
cerning Experimental Animals (Tianjin, revised in June 2004) 
and adhered to the Guiding Principles in the Care and Use of 
Animals of the American Physiological Society. The Ph.D.-
C7CTM phage display peptide library kit was used to screen 
specific peptides binding to human lung cancer xenografts 
on BALB/c-nu/nu athymic mice.
The phage display library kit is based on a combinatorial 
library of random peptide 7-mers fused to the N terminus of 
the minor coat protein (cpIII) of M13 phage. The random 
sequence is flanked by a pair of cysteine residues. Under 
nonreducing conditions, the cysteines spontaneously form 
a disulfide crosslink, resulting in phage display of cyclized 
peptides. The titer of the library is 2 × 1013 plaque-forming 
units (pfu). The library consists of 1.2 × 109 electroporated 
sequences (compared with 207 = 1.28 × 109 possible seven-
residue sequences). Extensively sequencing the naive library 
has revealed a wide diversity of sequences with no obvious 
positional biases. The Escherichia coli host strain ER2738 
(Arobust F+ strain with a rapid growth rate; New England 
Biolabs) was used for M13 phage propagation.
In vivo phage display screening  
and peptide synthesis
BALB/c-nu/nu athymic mice (female, 4–6 weeks) were 
used, and 2 × 107 NCI-H460 cells in 0.2 mL of Roswell 
Park Memorial Institute 1640 (RPMI-1640) medium were International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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subcutaneously injected in the right flank to   produce lung 
cancer xenografts. A Ph.D.-C7C phage display   peptide 
library, which contained 2 × 1011 pfu was mixed with 
200 µL of Dulbecco’s modified Eagle’s medium (DMEM), 
and injected into the mice through the tail vein when the 
tumor grew up to about 0.5 cm in diameter. After circula-
tion for 5 minutes, the mice were sacrificed, and perfused 
by injection of 50 mL phosphate-buffered saline through 
the heart to wash the unbounded phage. Then the tumors 
were harvested, weighed, and ground in 1 mL of DMEM-PI 
(DMEM containing the protease inhibitors PMSF [1 mM], 
aprotinin [20 µg/mL], and leupeptin [1 µg/mL]). The 
tissue was washed five times with ice-cold DMEM-PI 
  containing 1% bovine serum albumin. After centrifugation, 
the phage particles were amplified by ER2738 bacteria 
overnight at 37°C. The phages were titered on agar plates 
in the presence of IPTG/X-gel (1 mg/L) and tetracycline 
(40 µg/mL). The amplified phage was injected into the 
mice to repeat the above procedures. This screening was 
repeated for five rounds.17,27,34 At the end of the fifth round, 
the phage was eluted and titered on LB/ IPTG/X-gel 
plates. The phage clones were randomly selected, and 
the inserted DNA sequence was determined using primer 
5′-CCCTCATAGTTAGCGTAACG-3′ (New England Bio-
labs). The phage-displayed peptides were translated and 
synthesized according the DNA sequences.
synthesis of acetylated PAMAM 
dendrimer
The acetylated PAMAM dendrimer (PAMAM–Ac) was 
synthesized according to the method described in the 
literature.13,16,35 Briefly, 1.012 g (MW 14215, 71.2 µmol) 
of PAMAM dendrimer in 120 mL anhydrous methanol 
(MeOH) was reacted with 0.214 g (2.110 mmol) of acetic 
anhydride overnight at room temperature with stirring in the 
presence of 0.352 g (3.454 mmol) of triethylamine. After 
evaporation, the product was dialyzed for 3 days against 
phosphate-buffered saline and double-distilled water using 
the dialysis membrane (MWCO = 3500 Da), then lyo-
philized, and 1.165 g of PAMAM–Ac was obtained. The 
average number of acetyl groups grafted to each PAMAM 
molecule was determined by 1H nuclear magnetic resonance 
calibration.
conjugation of FITc to acetylated 
PAMAM dendrimer
FITC (38.2 mg, 98.1 µmol) was added dropwise into 40 mL of 
dimethyl sulfoxide (DMSO) solution containing 0.401 g (MW 
15433, 25.9 µmol) of PAMAM–Ac. The reaction   mixture was 
allowed to stir overnight. The product was   dialyzed against 
phosphate-buffered saline and double-distilled water using 
dialysis membrane (MWCO = 3500 Da) for 3 days in a 
dark room, and the adsorbance at 500 nm of the eluent was 
detected to ensure that all free FITC was removed. The 
product was then lyophilized in a dark room, and 0.387 g 
of PAMAM–Ac–FITC was obtained. The a  verage number 
of FITC molecules conjugated to each PAMAM molecule 
was determined by 1H nuclear magnetic resonance calibra-
tion and ultraviolet-visible adsorbance (Varian Cary 100 
bio ultraviolet-visible spectrophotometer).
conjugation of peptides to FITc-labeled 
dendrimer
The solution containing 9.1 mg (90.9 µmol) of succinic 
anhydride in 6 mL of anhydrous MeOH was added drop-
wise into a solution of 0.103 g (MW 16601, 6.2 µmol) of 
PAMAM–Ac–FITC and 24.5 mg of (0.242 mmol) trietha-
nolamine (TEA) in 90 mL of anhydrous MeOH with stirring. 
After overnight reaction at room temperature, the solvent 
was evaporated, and then the crude product was dialyzed 
(MWCO = 3500 Da) and lyophilized using the aforemen-
tioned method; 12.8 mg (MW 18001, 0.71 µmol) of the 
above product was then reacted with 2.0 mg (10.4 µmol) 
of 1-[3-(dimethylamino)-propyl]-3-ethyl-carbodimide HCl 
(EDC) in 4 mL of water for 3 hours. Then 9.2 mg (7.1 µmol) 
of the LCTP in 1 mL of DMSO was added dropwise to the 
above solution and stirred overnight. The crude product was 
dialyzed (MWCO = 3500 Da) using the aforementioned 
method, and the adsorbance at 275 nm of the elute was 
detected to ensure that all free peptide was removed. Then the 
product was lyophilized in a dark room. The average number 
of peptides conjugated to the dendrimer was determined 
using the Ellman assay.36 A standard curve was plotted with 
free LCTP. During the process, an excess of sodium sulfite 
was added to the peptide solution at pH 9.0 to cleave the 
disulfide bond, and the reaction was carried out in a dark 
room. The adsorbance at 412 nm was used to calculate the 
number of peptides conjugated to the dendrimer according 
to the standard curve.
Laser light-scattering assay
Samples of PAMAM–Ac, PAMAM–Ac–FITC, and PAMAM–
Ac–FITC–LCTP were filtered (pore size, 0.45 mm) and 
analyzed with a light-scattering spectrometer (BI-200SM; 
Brookhaven Instruments, Holtsville, NY), equipped with a 
digital correlator (BI-9000AT; Brookhaven Instruments) to 
determine the granulometric distribution of the conjugates 
at 532 nm.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cell culture
NCI-H460 cells were cultured in RPMI-1640 medium and 
293T cells in DMEM medium. The medium was supplemented 
with 10% fetal bovine serum, 1% penicillin, and 100 µg/mL 
streptomycin. Cells were grown at 37°C in 5% CO2.
cytotoxicity assay
The cytotoxicity of the PAMAM, PAMAM–Ac, PAMAM–
Ac–FITC, and PAMAM–Ac–FITC–LCTP were evaluated 
by the MTT assay. The 293T cells were seeded into 96-well 
plates at a density of 104 cells/well and incubated for 24 hours. 
The filtrate of the samples (0.22 µm) was added to the cells 
at different concentrations (0, 0.125, 0.25, 0.5, 1.0, 2.0, and 
4.0 µM). After incubation for another 24 hours, 25 µL of 
MTT solution (5 mg/mL in phosphate-buffered saline) was 
added to each well. Four hours later, the medium containing 
MTT was removed, and the samples in the wells were air 
dried. Acidic isopropanol (100 µL, 0.04 M HCl in absolute 
isopropanol) was added to dissolve the formazen crystals. The 
optical density of the solution was measured at 570 nm using a 
microplate reader (Labsystem; Multiskan, Ascent, Finland).
In vitro cellular uptake assay
293T and NCI-H460 cells were seeded in 24-well plates at 
a density of 104 cells/well. After 24 hours, the cells were 
incubated with PAMAM–Ac–FITC or PAMAM–Ac–FITC–
LCTP at different concentrations ranging from 0.05 to 
1.0 µM for 4 hours, or incubated with 0.25 µM of PAMAM–
Ac–FITC–LCTP at different intervals ranging from 0.5 to 
8.0 hours. To compare the uptake efficiency between 293T 
cells and NCI-H460 cells, the two cell lines were incubated 
with 0.5 µM of the conjugates for 4 hours. To examine the 
competitive uptake, 293T cells and NCI-H460 cells were 
preincubated with 20 µM free LCTP for 1 hour before the 
conjugates were added. At the end of incubation, the cells 
were trypsinized, washed with physiologic saline three times, 
and we then proceeded to fluorescence-activated cell sorting 
(FACS) analysis (Altra FCM; Beckman Coulter, Miami, FL). 
The uptake efficiency was expressed as the percentage of 
FITC-positive cells. The cells were also viewed under a con-
focal microscope (DMI6000B; Leica, Wetzlar, Germany) and 
an inverted fluorescence microscope. Images were recorded 
using CCD (ECLIPSE TE2000-U; Nikon, Tokyo, Japan).
In vivo targeting assay
BALB/c-nu/nu athymic mice with lung cancer xenografts were 
prepared as described earlier. Mice were used for experiment 
when the diameter of tumor xenografts reached 0.4–0.6 cm. 
The animals were randomly divided into two groups. A 0.3 mL 
solution of PAMAM–Ac–FITC or PAMAM–Ac–FITC–LCTP 
(10 µM in phosphate-buffered saline) was injected through 
the tail vein of the animal. Four hours later, the tumors and 
main organs (heart, liver, lung, spleen, kidney, thyroid, 
brain, and ovary) were harvested and proceeded to   imaging 
(KODAK IS in vivo FX; Kodak, New Haven, CT). The rela-
tive fluorescence intensity per unit area was calculated using 
KODAK 5.1 software (KODAK IS in vivo FX).
statistical analysis
The unpaired Student’s t-test was used to evaluate the sig-
nificance between experimental groups. A value of P , 0.05 
was considered to be statistically significant.
Results
screening and peptide synthesis
After five rounds of screening, 40 random phage clones 
were amplified and the DNA sequences were determined. 
The phage displayed peptide sequences were translated 
(see Table 1). The most frequent peptide sequence was 
ACPLSHSLIC, and the binding sequence with nonsmall 
cell lung cancer was the sequence between the two cysteine 
residues. In order to connect the peptide to the PAMAM 
dendrimer, the alanine residue was replaced by arginine. 
For  125I-labeling, a tyrosine residue was added to the end 
of the peptide. The final peptide sequence synthesized was 
RCPLSHSLICY, which was cyclized with two cysteine 
residues, marked LCTP (see supporting information for the 
HPLC and MS spectra of the synthesized peptide).
Preparation of PAMAM–Ac–FITc–LcTP 
conjugate
The synthetic route of PAMAM–Ac–FITC–LCTP con-
jugate is shown in Figure 1. The degree of PAMAM–Ac 
Table 1 The displayed peptide sequences of screening phage 
from in vivo lung cancer xenografts
Phage clone Peptide sequence Frequency
A-2 AcPLshsLIc 28/37
A-7 AcsVAPDNLc 3/37
B-11 AcAQsYhVWc 2/37
A-6 AcWFsNIAKc 1/37
A-13 AcshFVYgIc 1/37
B-3 AcVNgrMTDc 1/37
B-7 AcPLKANLsc 1/37
Notes: Forty phage clones were random selected from two plates (A and B) and 
37 phage displayed peptide sequences were identified. The first, second, and tenth 
residues are alanine, cysteine, and cysteine, respectively. The inner random seven 
peptides were cyclized by the two cysteine residues.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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acetylation was measured by 1H nuclear magnetic resonance 
(300 mHz, D2O); the aliphatic peaks appear at 1.80 ppm, 
2.24 ppm, 2.46 ppm, 2.64 ppm, 2.93 ppm, 3.12 ppm, 
3.23 ppm, and 3.30 ppm. The integration ratio of methyl-
ene protons signal of –CH2C(O)– at δ2.24 ppm (248 H) and 
methyl protons signal of –C(O)CH3 at δ1.80 ppm was 2.84, 
indicating that about 29 acetyl groups were grafted to each 
PAMAM molecule (PAMAM–Ac29). Conjugation of FITC 
to PAMAM–Ac was characterized by  1H nuclear mag-
netic resonance (300 mHz, D2O) and   ultraviolet–visible 
  spectrum. The aliphatic peaks appear at 1.80 ppm, 
2.23 ppm, 2.44 ppm, 2.63 ppm, 2.94 ppm, 3.11 ppm, 
3.29 ppm, and 3.30 ppm. The aromatic peaks at 6.37 ppm, 
6.96 ppm, 7.42 ppm, and 7.67 ppm   corresponded to 
the protons in FITC. FITC has a characteristic   absorbance 
peak at around 500 nm and not for PAMAM–Ac and 
the peptide (  Figure 2). The number of FITC conjugated 
to PAMAM–Ac was about 3–4, which was determined 
based on the   standard calibration curve of free FITC. 
The number of LCTP grafted to PAMAM–Ac–FITC was 
7–8 by   Ellman assay (see supporting information for the 
1H nuclear magnetic resonance spectra of PAMAM–Ac, 
  PAMAM–Ac–FITC, and PAMAM–Ac–FITC–LCTP).
cytotoxicity assay
As shown in Figure 3, when the concentration of the polymers 
was higher than 2 µM, the cytotoxicity of PAMAM–Ac, 
PAMAM–Ac–FITC, and PAMAM–Ac–FITC–LCTP was 
lower than that of unmodified PAMAM. The cells viability 
was over 88%, which suggests that the PAMAM–Ac–FITC–
LCTP conjugate has good biocompatibility.
In vitro cellular uptake assay
Figure 4A shows the uptake efficiencies of the two conju-
gates for 293T cells over 4 hours. The uptake efficiencies 
of both conjugates were nearly of equal value and were 
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the PAMAM–Ac–FITC-treated NCI-H460 cells. A clear 
image was observed under confocal microscopy. Figure 5E 
shows the image of PAMAM–Ac–FITC–LCTP-treated 
NCI-H460 cells.
In vivo targeting assay
The distribution of PAMAM–Ac–FITC and PAMAM–Ac–
FITC–LCTP in different organs was evaluated by measuring 
the fluorescence intensity of each organ at 4 hours after intra-
venous injection. Figure 6 showed the fluorescence density of 
the main organs. The highest density of the two conjugates 
was found in the kidney next in the tumors, followed by the 
brain and the lung. There was no difference in the distribution 
of the two conjugates among all the other organs, except in 
the tumors where the distribution of PAMAM–Ac–FITC–
LCTP was significantly higher than that of PAMAM–Ac–
FITC (P , 0.01).
Discussion
In vivo phage display has been proven to be a useful method in 
isolating organ- or tumor-specific binding probes. The random 
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concentration-dependent. However, although the uptake 
efficiencies of the two conjugates by NCI-H460 cells were 
also concentration-dependent, but the uptake efficiency of 
the PAMAM–Ac–FITC–LCTP was much higher than that 
of PAMAM–Ac–FITC (Figure 4B). The cellular uptake of 
the conjugates by both cell lines was time-dependent, but 
reached saturation after incubation for 4 hours (Figure 4C). 
Under the same conditions, the uptake of PAMAM–Ac–
FITC–LCTP by NCI-H460 cells was threefold higher than 
that of PAMAM–Ac–FITC, and more than threefold higher 
than the uptake of the two conjugates by 293T cells. When 
preincubated with free LCTP, uptake of PAMAM–Ac–FITC–
LCTP by NCI-H460 cells was effectively decreased, but for 
293T cells and PAMAM–Ac–FITC there was almost no 
change (Figure 4D).
The uptake of PAMAM–Ac–FITC and PAMAM–Ac–
FITC–LCTP by the cells was directly visualized under the 
inverted fluorescence microscope. As shown in Figure 5, 
the fluorescence signal of the PAMAM–Ac–FITC–LCTP-
treated NCI-H460 cells (Figure 5D) was much stronger 
than those from the two conjugates-treated 293T cells and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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sequence oligonucleotides were inserted into a specific site 
of phage DNA, then random sequence peptides or proteins 
were expressed and exposed on the phage surface. Because 
organs and tumors carry unique marker molecules,27,37 phage 
display can be used to screen organ- or tumor-specific peptide 
sequences for targeted drug delivery. The present study used 
an in vivo phage display method to screen peptides. Cyclic 
peptides have higher stability and binding capability,38 so 
the Ph.D.-C7C phage display peptide library kit was used, in 
which the inserted peptide were cyclized by two cysteine resi-
dues. As shown in the Table, the phage inserted ACPLSHSLIC 
sequence was amplified and enriched. Among the total of 
Figure 5 In vitro evaluation of the conjugates (fluorescence-labeled acetylated polyamidoamine and fluorescence-labeled acetylated polyamidoamine lung cancer targeting 
peptide) targeting to 293T and NCI-H460 cells determined by inverted fluorescence microscopy. The cells were incubated with the conjugates (0.5 µM) for 4 hours. 
100 × (A) 293T cells incubated with fluorescence-labeled acetylated polyamidoamine. B) 293T cells incubated with fluorescence-labeled acetylated polyamidoamine lung 
cancer targeting peptide. C) NCI-H460 cells incubated with fluorescence-labeled acetylated polyamidoamine. D) NCI-H460 cells incubated with fluorescence-labeled 
acetylated polyamidoamine lung cancer targeting peptide. E) local amplification of D.
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37 phage displayed peptide sequences, 28 were the same, 
which was the ACPLSHSLIC peptide.
The cationic PAMAM has hemolytic toxicity.39 Several 
methods to decrease the hemolytic toxicity of PAMAM have 
been reported, one of which is the PEG modification.40–42 
PEGylation can inhibit the nonspecific interactions between 
PAMAM and biomolecules and improve the biocompatibility 
of PAMAM, and can also decrease the immunogenicity and 
antigenicity of PAMAM. Another method is acetylation, 
which can decrease the positive charge density of PAMAM. 
In our studies, partially acetylated PAMAM displayed higher 
cell viability than PAMAM by the MTT assay. Further 
conjugation of FITC and the LCTP to the PAMAM–Ac 
had no influence on the biocompatibility of the dendrimer 
(Figure 3).
The uptake of PAMAM–Ac–FITC–LCTP by both 
293T and NCI-H460 cells was found to be time- and dose-
dependent. However, the uptake efficiency of PAMAM–
Ac–FITC–LCTP by NCI-H460 cells was much higher than 
that of PAMAM–Ac–FITC. In contrast, the uptake of both 
conjugates by 293T cells was very low. Similar results were 
previously reported by Hill et al16 and Shukla et al.43 In their 
studies, RGD peptide drove PAMAM conjugates specifically 
to MDPC-23 and HUVEC cancer cells, and enhanced cellular 
uptake. The free LCTP could greatly decrease NCI-H460 cell 
uptake of PAMAM–Ac–FITC–LCTP, but had no effect on 
NCI-H460 cell uptake of PAMAM–Ac–FITC and 293T 
cell uptake of PAMAM–Ac–FITC–LCTP and PAMAM–
Ac–FITC. These observations suggest that LCTP played an 
important role in driving the conjugates highly and selectively 
to bind the membrane of NCI-H460 cells, thus facilitating 
the endocytosis process.
Because the penetration of FITC fluorescence through the 
body of mice is weak, in vivo imaging of live athymic mice 
bearing nonsmall cell lung cancer tumors cannot provide an 
exact fluorescence intensity. In this study, the tumors and 
organs were harvested and imaged ex vivo. The   distribution 
of PAMAM–Ac–FITC and PAMAM–Ac–FITC–LCTP conju-
gates in each organ was almost the same except that the tumors 
had significantly higher uptake of PAMAM–Ac–FITC–LCTP 
than PAMAM–Ac–FITC (P , 0.01). This result suggests that 
the targeting effect of LCTP might enhance the permeability 
of PAMAM–Ac–FITC–LCTP in nonsmall cell lung cancer 
tumor. Indeed, the difference of tumor uptake for the two 
conjugates was not remarkable, and more experiments need 
to be done to improve the targeting effect of the conjugate. 
The distribution of the conjugates among different organs was 
found in the following order: kidney . tumor $ brain . lung 
. thyroid $ ovary. liver $ spleen $ heart (Figure 6). The 
highest distribution of the conjugates was found in the kidney 
4 hours after   injection which is probably due to the fact that 
kidney is the main organ that excretes waste out of the body. 
And four hours after the injection, part of the conjugates 
had moved to the metabolic system, which is a phenomenon 
often observed in drug pharmacokinetic studies.15,25 It was 
interesting that the distribution of the conjugate in the brain 
was similar to that in the tumors, indicating that this PAMAM 
conjugate can penetrate the blood–brain barrier and enter the 
brain.44,45
Although antibody, folic acid, and biotin are often used 
as targeting agents, the peptides screened here by an in vivo 
phage display method could target the unique receptors 
expressed by cancer cells, thus remarkably improved the 
targeting capability for chemotherapy.
Conclusion
In summary, NCI-H460 cell-specific LCTP was screened by 
the phage display method and conjugated to the acetylated 
PAMAM dendrimer. The specific LCTP-modified PAMAM 
dendrimer could be easily taken up by NCI-H460 cells in 
vitro and by tumors in vivo. These results indicate that the 
LCTP–dendrimer conjugate might be a useful drug carrier 
for cancer clinical diagnosis and treatment.
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Figure S1 1h nuclear magnetic resonance spectrum (300 mhz, D2O) of the acetylated polyamidoamine.
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Figure S2 1h nuclear magnetic resonance spectrum (300 mhz, D2O) of the fluorescence-labeled acetylated polyamidoamine.
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Figure S3 1h nuclear magnetic resonance spectrum (300 mhz, D2O) of the fluorescence-labeled acetylated polyamidoamine lung cancer targeting peptide.International Journal of Nanomedicine
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